The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Home | Video pages | Webcast | Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: what is the link